Blog

T cells

Preparing for Cell and Gene Therapy 3.0

Patient data is mission-critical data — especially in cell and gene therapy.

In cell and gene therapy (CGT), the patient is the process is the product. Patient and/or donor data is an essential part of manufacturing and delivery, in unique and complex ways. It is also fundamental to patient safety and product and process knowledge, providing the opportunity to reduce risk and accelerate development.

Read More
January 8, 2020

Data management for advanced therapies, Part 3: working with living cells

Note: this post is the third in an eight-part series on data management strategies for personalized therapies, such as cell...

December 30, 2019

Advanced therapy supply chains: lessons from 100 meetings

You can learn a lot in 100 meetings. In 2019, I conducted more than 100 discussions on advanced therapy supply...

December 17, 2019

WoVen, a podcast from Canaan featuring Amy DuRoss

One of Vineti’s board members, Nina Kjellson, General Partner, at Canaan started a podcast called WoVen, about women who venture. We’re excited to...

December 4, 2019

Data management for advanced therapies, Part 1: the need for new strategies

Note: this post is the first of an eight-part series on data management strategies for personalized therapies, such as cell...

December 4, 2019

Data management for advanced therapies, Part 2: unique data features

Note: this post is the second of an eight-part series on data management strategies for personalized therapies, such as cell...

November 26, 2019

Design for Healthcare IRL at Vineti, a Meetup

More and more of today’s healthcare happens online and digital is just one part of the picture. Much of the...

November 15, 2019

Eight million pages, the Space Shuttle, and other highlights from BMWS 2019

If you’re producing cell therapy products for 10,000 patients a year, how many release tests will be required? If making...

November 6, 2019

More kaizen for cell and gene therapy

Today, Vineti is excited to announce a new partnership with a global contract manufacturing company serving cell and gene therapies — and...

October 30, 2019

Chain of Identity and Chain of Custody in personalized therapies — core differences from traditional pharma

In pharmaceutical manufacturing, Chain of Identity and Chain of Custody may not be new — but in advanced therapy manufacturing,...

October 23, 2019

Q&A with Dr. Mike Pellini: the need for advanced software to scale cell and gene therapies

Mike Pellini, M.D., is a member of Vineti’s Board of Directors, a Managing Partner at Section 32, and the former...

October 17, 2019

Supply chain vs. value chain: need-to-know essentials

In a recent blog post about Quality Risk Management, we talked about the importance of considering the entire “value chain” when...

October 10, 2019

Design for personalized therapies: reframing “delight” as the goal

Sometimes, in the world of UX and product design, “delight” means getting out of the way. Read about general approaches...